Roche Plans $50 Billion Investment in the U.S. Amid Ongoing Pharma Tariff Concerns

A photo showing the logo of Swiss pharmaceutical giant Roche in Basel.
SEBASTIEN BOZON | AFP | Getty Images

Swiss pharmaceutical giant Roche on Tuesday announced a commitment to invest $50 billion in the U.S. over the next five years, in light of concerns regarding potential new White House tariffs on pharmaceutical goods from abroad. The investment is expected to create over 12,000 jobs, with 1,000 positions directly within the company and the remainder aimed at supporting new U.S. manufacturing capabilities.

Roche plans to fund the establishment of state-of-the-art research and development (R&D) sites, while enhancing and expanding manufacturing facilities in Indiana, Pennsylvania, Massachusetts, and California. A new R&D site in Massachusetts will focus on AI research and serve as a hub for research into cardiovascular, renal, and metabolism treatments.

The funding package will also be utilized to construct a new 900,000 square foot manufacturing center in an undisclosed location, designed to support Roche’s expanding portfolio of next-generation weight loss medicines. Once the new manufacturing capacity investments are completed, Roche stated it will export more medicines from the U.S. than it imports.

Pharmaceutical companies have been taking steps to strengthen their U.S. presence in response to threats from President Donald Trump regarding the potential end of the industry’s exemption from import tariffs. “We’re going to be announcing very shortly a major tariff on pharmaceuticals,” he remarked earlier this month.

This developing story is being updated.